🧪 TrialInsufficient
Registered Phase 4 interventional trial (not yet recruiting). Prediabetes affects millions of adults worldwide and carries a high risk of progression to type 2 diabetes. Mazdutide is a once-weekly injectable drug that activates both GLP-1 and glucagon receptors, lowering blood sugar and body weight simultaneously. This study (DREAM-PRE) tests whether mazdutide can help adults with prediabetes return to normal blood sugar levels. Approximately 150 adults aged 18-75 years with prediabetes and BMI ≥22 kg/m² will be randomly assigned in equal numbers to one of three groups: mazdutide 4 mg once wee
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (not yet recruiting). This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered N/A interventional trial (recruiting). The purpose of this study is to examine the effects of resistance exercise, such as weightlifting, on retention of muscle mass and mental health in individuals taking GLP-1 RAs (an obesity medication). Resistance exercise is focused on increasing the strength of participants' muscles, such as how much participant can lift. •The duration of this study is 3 months. This includes: * Orientation session to explain study protocol, exercise program, and complete questionnaire about participants' medical history and lifestyle. * Two health assessments
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (not yet recruiting). Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and increased physical activity. All participants will be randomized to at least 76 weeks of treatment to evaluate the effects on long term body weight changes, tolerability, and safety. In addition, the study will compare the eff
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (not yet recruiting). This study is a multicenter, randomized, open-label, parallel-group, semaglutide injection-controlled clinical trial. It aims to evaluate the non-inferiority of UBT251 Injection in glycemic control compared with Semaglutide Injection after 36 weeks of continuous administration in study participants with Type 2 Diabetes Mellitus (T2DM) and inadequate glycemic control on oral antidiabetic medications.A total of 956 participants are planned to be enrolled, including the UBT251 Injection 2 mg group, 4 mg group, 6 mg group, and Semagluti
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered observational trial (recruiting). Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may contribute to these differences in treatment outcomes. The aim of this prospective cohort study is to investigate whether a Genetic Risk Score (GRS) and s
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered N/A interventional trial (active not recruiting). The goal of this clinical trial is to learn whether a mindfulness-based nutrition group program is feasible and acceptable for adults with obesity who are taking GLP-1 receptor agonist medication and receiving usual medical care, including dietetic counselling. The main questions this study aims to answer are: Can this group program be successfully carried out with adults receiving GLP-1 treatment? Do participants find the program useful, acceptable, and manageable? Are participants willing to attend the sessions, complete the home e
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered observational trial (recruiting). This study will assess the impact of genetic markers, microbiological (microbiome) and behavioral factors on tolerance, adherence and effectiveness of dual GLP1/GIP RA in the treatment of obesity. 200 consecutive patients who meet all inclusion and none of the exclusion criteria will be enrolled.
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered Phase 1/Phase 2 interventional trial (recruiting). Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited. Growing evidence suggests that inflammation in the brain and the body plays a key role in the onset and progression of AD. In particular, immune cells called regulatory T cells (Tregs), which normally help control inflammation, are impaired in AD individuals. This leads to increased activity of harmful immune pathways that worsen brain injury. Interleukin-2 (IL-2) i
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered N/A interventional trial (recruiting). This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and part
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered Phase 1/Phase 2 interventional trial (not yet recruiting). Duchenne Muscular Dystrophy (DMD) is a rare, genetic disease that leads to muscle weakness, breathing difficulties, heart disease, and early death. Approximately half of individuals with DMD have elevated body mass indices (BMIs) in the overweight or obesity range. High BMI is due to a combination of factors including limited mobility and steroid medications, which are used to treat DMD. There are new medications, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) that promote weight loss in the general population. GLP-1
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered observational trial (completed). This study evaluated whether a 16-week weight-loss program using tirzepatide before elective ventral and incisional hernia surgery could improve surgical readiness and outcomes in patients with obesity. In this retrospective multicenter study, 109 patients entered the program, and 91 completed treatment and underwent surgery. Participants achieved an average weight loss of 13.8%, and all patients who completed the program reached the target weight required for surgery. Compared with a control group of obese patients who underwent hernia repair withou
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered Phase 2 interventional trial (not yet recruiting). The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered observational trial (enrolling by invitation). The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers. The main questions it aims to answer are: 1. Is obesity medication usage is associated with reduced body mass index (BMI) and weight? 2. Is obesity medication usage is associated with reduced utilization of emergency department and inpatient care or obesity-related conditions over time? 3. Is obesity medication
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (not yet recruiting). The goal of this clinical trial is to learn the efficacy of combination therapy with tirzepatide, empagliflozin and pioglitazone versus standard therapy in newly diagnosed type 2 diabetes. The main objectives to achieve are: 1. To compare efficacy of the triple combination therapy against standard therapy in achieving type 2 diabetes remission in patients newly diagnosed with T2DM. 2. To compare the effects on β-cell function and glycemic control of the triple combination therapy against standard therapy in patients newly diagnosed
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered N/A interventional trial (recruiting). Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatr
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered expanded_access trial (available). Provide pre-approval single patient expanded access of retatrutide for patients.
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered Phase 4 interventional trial (not yet recruiting). This multicenter, randomized, open-label, blinded-endpoint trial evaluates whether weekly subcutaneous tirzepatide for 12 months reduces atrial fibrillation (AF) recurrence after catheter ablation in adults with obesity and heart failure with preserved ejection fraction (HFpEF). HFpEF is diagnosed by direct intraprocedural measurement of mean left atrial pressure (mLAP ≥ 15 mmHg at rest) during the ablation procedure, providing a hemodynamically anchored, homogeneous study population free from the diagnostic ambiguities of N-termina
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered observational trial (active not recruiting). Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered observational trial (active not recruiting). Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
ClinicalTrials.gov · Jun 2026View trial ↗